Navigation Links
Treatment for Cigarette, Alcohol & Drug Use During Pregnancy Dramatically Improves Outcomes for Mom and Baby, Kaiser Permanente Study Shows
Date:6/26/2008

low birth weight and neonatal ventilation were dramatically higher for the 156 untreated substance abusers than the 2,073 women in the Early Start program:

-- Risk of stillbirth was 16.2 times higher for women who were screened but did not accept assessment or treatment than those who received Early Start treatment

-- Risk of placental abruption was 6.8 times higher for women who were screened but did not accept assessment or treatment than those who received treatment

-- Risk of pre-term delivery was 2.1 times higher for women who were screened but did not accept assessment or treatment than those who received treatment

-- Risk of low birth weight (under 5.5 pounds) was 1.8 times higher for women who were screened but did not accept assessment or treatment than those who received treatment

-- Risk of neonatal ventilation was 2.2 times higher for women who were screened but did not accept assessment or treatment than those who received treatment.

The women who went through the Early Start program had the same statistical risks of stillborn, preterm delivery, placental abruption as the control group of women who did not use any cigarettes, alcohol or drugs during their pregnancy.

"The key message here to women who are currently smoking, drinking or using other drugs, or who recently tried to stop, is that it is not too late to seek help when you find out you are pregnant," said Dr. Goler. "The sooner women ask for help, the better the health outcomes will be for themselves, and their babies. My message to all pregnant women, as well as women who are trying to conceive, is to stop all alcohol, cigarette and drug use."

Launched in 1990, Kaiser Permanente's Early Start program integrates obstetric care with substance abuse treatment for pregnant women in three ways: all women are screened by questionnaire for drug, cigarette and alcohol use, and by urine toxicology testing with signed consent; a licensed substance
'/>"/>

SOURCE Kaiser Permanente
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Rheumatoid Arthritis Treatment Guidelines Updated
2. Because of Its Ability to Generate Higher Total Sales in the United States and Europe, Lucentis Will Earn Clinical Gold Standard Status by 2011 for the Treatment of Diabetic Retinopathy
3. Adoption of Minimally Invasive Prostate Cancer Treatment Options Slow
4. Leading Eating Disorder Treatment Center Identifies Popular Diet Myths
5. California Drug Rehab Program Launches New Life Skills Classes to Young Adults as Substance Abuse Treatment
6. State policies influence drug treatment programs
7. National Headache Foundation Offers Statement, Experts on Appropriate Use of Medications for Migraine Treatment
8. Medical Pot Ineffective as Acute Pain Treatment
9. Younger Patients Seeking More Aesthetic Treatments
10. Prescribed Meds Still Best Treatment for Alcoholism
11. Revolutionary Therapy: Needle-Free Technology for the Treatment Of Blinding Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... FACE Skincare~Medical~Wellness, a multiaward-winning leader in bringing ... to take fifteen years off of an individual’s ... treatment introduced that is the first and only ... lines and wrinkles on the Décolleté. This new ... the stubborn vertical lines between the upper breast ...
(Date:2/27/2015)... California (PRWEB) February 27, 2015 ... announced today the launch of its CloudPoint™ ... enabling the digital production of monolithic zirconia crowns ... affordable means of providing the CAD/CAM-produced restorations that ... digital portal through which cases can be scanned, ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Insight ... Medical to advance the development of an in-line ... new solution is being developed in direct response ... only 73% accuracy and error margins with potentially ... error-free output measurement and provide trending data analysis ...
(Date:2/27/2015)... 2015 The Lymphoma Research Foundation (LRF) ... funding innovative lymphoma research and serving the lymphoma community ... and patient services – is continuing to make its ... the greater Miami area to host Swirl, A Wine ... Miami Beach on Thursday, March 26, 2015. This year’s ...
(Date:2/27/2015)... Chicago, IL (PRWEB) February 27, 2015 ... Assistant Professor of Biomedical Engineering at Duke University, ... modification for boys and young men with Duchenne ... 18 in Nature Communications, and Gersbach will discuss ... be held March 11-14 in Washington, D.C. , ...
Breaking Medicine News(10 mins):Health News:Face Skincare Announces New Combination Therapy 2Health News:Glidewell Laboratories Announces Release of CloudPoint™ FastScan™ and FastDesign™ 2Health News:Glidewell Laboratories Announces Release of CloudPoint™ FastScan™ and FastDesign™ 3Health News:Output Medical Joins Insight Accelerator Labs 2Health News:Output Medical Joins Insight Accelerator Labs 3Health News:Lymphoma Research Foundation Returns to Miami Beach For Exclusive Swirl Wine Tasting Event 2Health News:Statement: New MDA-Funded Genetic Therapy Technique Targets DMD 2
... is sufficient follow-up after breast conserving therapy (BCT) for ... at the Cancer Imaging and Radiation Therapy Symposium in ... for Radiation Oncology (ASTRO) and Radiological Society of North ... the clinical relevance and utility of an interval mammogram ...
... Reinberg HealthDay Reporter , THURSDAY, April 28 ... drug Didronel reduces plaque buildup in the aorta better ... While Lipitor is a statin that lowers cholesterol, Didronel ... which are typically taken by people with osteoporosis. ...
... April 28 (HealthDay News) -- Two new drugs that ... unanimously recommended for approval by a panel of U.S. health ... committee voted 18-0 that telaprevir, made by Vertex Pharmaceuticals Inc., ... rashes that has been reported among those taking it. On ...
... A study by Henry Ford Hospital shows a direct association ... also shows that in most cases the rupture heals on its ... "In the past, many otolaryngologists have wondered if surgery is ... study show that 97 percent of cases healed on their own ...
... -- Boceprevir, a new medication from Merck & Co. that ... Wednesday from a panel of experts convened by the U.S. ... of two new medications against hepatitis C that are up ... and the second medicine, telaprevir, could revolutionize treatment of hepatitis ...
... the Center for Translational Social Neuroscience (CTSN) at Emory ... model to screen the effectiveness of drugs to treat ... drug Emory researchers have shown enhances behavioral therapy for ... Giving female voles D-cycloserine, which is thought to facilitate ...
Cached Medicine News:Health News:Bone Drug Plus Statin Better at Fighting Plaque in Aorta: Study 2Health News:Bone Drug Plus Statin Better at Fighting Plaque in Aorta: Study 3Health News:New Hepatitis C Drugs Close to Gaining FDA Approval 2Health News:New Hepatitis C Drugs Close to Gaining FDA Approval 3Health News:Study: Cotton swabs prove problematic for ear health 2Health News:New Hepatitis C Drug Close to Gaining FDA Approval 2Health News:Social bonding in prairie voles helps guide search for autism treatments 2Health News:Social bonding in prairie voles helps guide search for autism treatments 3
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
(Date:2/27/2015)... --  Synageva BioPharma Corp. (Synageva) (NASDAQ: ... products for rare diseases, joins the National Organization ... Rare Diseases™ (EURORDIS™), The Global Genes Project™, and ... Day. On the last day of ... participants conduct special events to raise awareness and ...
(Date:2/27/2015)... 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... announced financial results for its first quarter ended December ... ended December 31, 2014, revenue was $1,336,685. Operating expenses ... or $0.02 per share.  Covalon,s President ... very pleased with the significant progress we have made ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... Reportlinker.com announces that a new market research ... Macular Degeneration Therapy Area Pipeline Report ... Macular Degeneration Therapy Area Pipeline Report contains detailed ... report provides insight into the pipeline status of ...
... April 13, 2011 Allscripts (NASDAQ: MDRX ) ... the three months ended March 31, 2011 after the stock ... host a conference call and webcast to discuss the company,s ... on the same day. (Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO ) ...
Cached Medicine Technology:Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 2Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 2Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 4
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Severe revision options for the knee and hip...
Medicine Products: